Virtual biotech accelerator Autobahn Labs is amping up speed with a new Charles River Laboratories partnership in which the former will gain access to CRL’s drug development capabilities, according to a Wednesday release.

Roche has punted a Pompe disease gene therapy from its pipeline after weighing up the competitive landscape. The Swiss drugmaker made the change in a second-quarter update that also featured news of TIGIT trial closures and a commitment not to make “huge cuts” to the organization.

Clinical trials are frightening endeavors for biotech investors. Expensive and fraught with risk, a trial’s failure can seriously lighten an investor’s pockets with little hope of recourse. After gaining approval from global insurance marketplace Lloyd’s of London, a new partnership is set to use a machine learning algorithm to offer investors insurance on clinical trial funding.

When it comes to developing new pain drugs, the placebo effect is a powerful but baffling force. It’s well known that expectation alone can be enough to provide pain relief, even if the “treatment” is a sham with no real medical benefit. Though the relief provided by a placebo can be enough to make clinical trials for new pain medications fail, how our brains produce such strong pain relief through belief alone is largely a mystery.

Three months after scoring FDA approval for a hemophilia B gene therapy, Pfizer has posted phase 3 data suggesting it may be able to pull off the same success with a different candidate in hemophilia A.

OSE Immunotherapeutics is hoping to show Servier what they walked away from. Around one year after the French drugmakers split up, the biotech has reported midphase data on an anti-IL-7 antibody lusvertikimab in ulcerative colitis showing a potential improvement in symptoms.

After 14 years on the board of Moderna, the biotech that became a household name after developing an mRNA vaccine for Covid-19, chemical engineer Robert Langer, Sc.D., is retiring from the company’s board.

A study by the National Institutes of Health (NIH) found that artificial intelligence could help accurately diagnose patients—but the large language model still stumbled when it came to clearly explaining its answers.

A clutch of Johnson & Johnson veterans have burst onto the biotech scene, launching Third Arc Bio with $165 million to take multifunctional antibodies into the clinic in solid tumors and autoimmune diseases.

Moderna recently became the latest biopharma to score an approval to prevent respiratory syncytial virus (RSV), but Merck & Co. hopes to be the next in line with new data showing a monoclonal antibody reduced the incidence of RSV-related infections in infants.